Loading...
ROCO
4157
Market cap221mUSD
Nov 13, Last price  
9.74TWD
Name

Taigen Biopharmaceuticals Holdings Ltd

Chart & Performance

D1W1MN
ROCO:4157 chart
P/E
—
P/S
46.02
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.02%
Rev. gr., 5y
49.29%
Revenues
151m
+22.35%
14,906,000225,732,00040,440,00069,875,000104,598,00078,004,000146,021,000553,208,00029,618,00020,314,00023,422,0001,294,522,00036,230,000123,134,000150,651,000
Net income
-39m
L
-2,285,618,00042,837,000-468,398,000-432,193,000-403,718,000-412,994,000-250,034,000746,378,000-343,210,000-295,685,000-404,819,000775,618,000-237,164,000136,731,000-38,583,000
CFO
-173m
L
-196,430,000-379,229,000-141,356,000-458,457,000-540,034,000-592,563,000-152,832,000-266,926,000-254,928,000-342,520,000-242,098,000629,069,000-21,269,0007,459,000-173,088,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.
URL
https://www.taigenbiotech.com/
IPO date
Aug 30, 2013
Employees
Domiciled in
TW
Incorporated in
KY

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT